II International Frontiers in Oncology. The present and future of the RAS pathway: from function and genomics to inhibition

II International Frontiers in Oncology. The present and future of the RAS pathway

Museum of the University of Navarra (MUN). October 5-7, 2015, Pamplona, Spain


Monday October 5

16:30h – 17:30h     MEETING REGISTRATION
17:30h – 18:00h     WELCOME. Opening remarks by institutional authorities

Chair: Silvestre Vicent (Center for Applied Medical Research -CIMA-, SPAIN), Ignacio Gil-Bazo (Clínica Universidad de Navarra) and Alejandro Sweet-Cordero (Stanford University, USA)

Mariano Barbacid (Spanish National Cancer Research Center, -CNIO-, SPAIN)
“Erradicating K-Ras driven cancer: A chimera or a realistic goal?”
Frank McCormick (UCSF Helen Diller Family Comprehensive Cancer Center, USA)
“Targeting K-Ras Induced Stemness”

19:30h – 21:00h     WELCOME COCKTAIL

Tuesday October 6

8:30h – 10:45h     SESSION 1: RAS regulation

Chair: Eugenio Santos (Cancer Research Center, SPAIN)

Chris Counter (Duke University Medical Center, USA)
“Codon Bias: The silent secret of RAS oncogenes”
Piero Crespo (IBBTEC, Santander)
“Ras activation at the Golgi Complex induces apoptosis”
Kevin M. Haigis (Beth Israel Deaconess Medical Center, USA)
“Activation of K-Ras by non-canonical missense mutations”

– Short talks:
Matthias Drosten (Spanish National Cancer Research Center, -CNIO-, SPAIN)
“Are K-RasG12V and H-RasG12V equivalent oncogenes?”
David G. Matallanas (Systems Biology Ireland-UCD, IRELAND)
“Mapping Ras specific signalling from different subcellular compartments using OMICs approaches”

10:45h – 11:15h     COFFEE BREAK
11:15h – 13:45h     SESSION 2: Functional Genomics and Systems Biology of RAS

Chair: Silve Vicent (CIMA, SPAIN)
Alejandro Sweet-Cordero (Stanford University, USA)
“Identification of novel regulators of oncogenic KRAS using systems biology and functional genomics”
William C. Hahn (Dana-Farber Cancer Institute/Broad Institute, USA)
“Systematic approaches to target RAS signaling in cancer”
Michael A. White (UT Southwestern Medical Center, USA)
“Chemically addressable subtypes of KRAS lung cancer”

– Short talks:
Shivan Sivakumar (Department of Oncology, University of Oxford)
“Kras associated regulatory hubs in Pancreatic Cancer”
Clara Lubeseder-Martellato (Technical University Munich, GERMANY)
“Oncogenic Kras depends on fluid-phase endocytosis for acinar-ductal metaplasia”

15:30h – 17:45h     SESSION 3: Targeting RAS pathway effectors in gastrointestinal tumor patients

Chair: Salvador Martin-Algarra (Clínica Universidad de Navarra, SPAIN)
Jens Siveke (Technical University Munich, GERMANY)
“Targeting strategies in Ras-driven pancreatic cancer”
Josep Tabernero (Vall D’Hebron Institute of Oncology, SPAIN)
“Targeting the ERK pathway in colorectal cancer”
Manuel Hidalgo (Spanish National Cancer Research Center, -CNIO-, SPAIN)
“Targeting Ras-MEK pathway in pancreatic ductal adenocarcinoma”

– Short talks:
Mariano Ponz (Cold Spring harbor Laboratory, USA)
“Human and mouse pancreatic cancer organoid models identify differential ERBB pathway activation following MEK and AKT inhibition”
Pan-Yu Chen (Koch Institute for Integrative Cancer Research at MIT, USA)
“Survival of pancreatic cancer cells lacking KRAS function”

Wednesday October 7

8:30h – 10:45h    SESSION 4: RAS network (30+5 min. talks)

Chair: Luis Montuenga
Eugenio Santos (Cancer Research Center, -CIC-, SPAIN)
“Functional specificity of RasGEF isoforms of the GRF and SOS families”
Karen Cichowski (Brigham and Women’s Hospital, USA)
“An expanding family of RasGAP tumor suppressors in cancer”
Xosé R. Bustelo (Cancer Research Center, CIC, SPAIN)
“Ras-related proteins as direct oncogenic drivers”
Claudia Wellbrock (The University of Manchester, UK)
“Tumour heterogeneity in MAPK pathway driven melanoma”

10:45h – 11:15h    COFFEE BREAK
11:15h – 13:30h    SESSION 5: RAS signaling

Chair: Alejandro Sweet-Cordero (Stanford University, SPAIN)
Julian Downward (London Research Institute, Cancer Research UK)
“Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches”
Reinhold Schäfer (Charite Comprehensive Cancer Center, GERMANY)
“RAS pathway-mediated impact on transcriptome”
Silve Vicent (Center for Applied Medical Research, -CIMA-, SPAIN)
“An integrative cross-species, cross-tumors approach to identify RAS dependencies”

– Short talks:
Imanol Arozarena (University of Huddersfield, UK)
“Oncogenic BRAF regulates melanoma invasion through the cGMP-phosphodiesterase PDE5A: clinical (and legal) implications”
Deborah Burkhart (University of Cambridge, UK)
“The oncogenicity of Myc-Ras cooperation teters on a careful balance of proliferation and apoptosis”

16:00h – 17:45h     SESSION 6: Targeting the RAS pathway in lung cancer

Chair: Ignacio Gil-Bazo (Clínica Universidad de Navarra, SPAIN)
Egbert Smit (VU University Medical Center, Amsterdam, HOLLAND)
Title to be announced…
Luis Paz-Ares (Hospital 12 de Octubre and Spanish National Cancer Center -CNIO-, SPAIN)
“Ras driven lung cancer: a difficult disease to target in the clinic”

– Short talks:
Ji Luo (National Cancer Institute, USA)
“The Exon Junction Complex Regulates KRAS Splicing and Confers Non-oncogene Addiction in KRAS Mutant Cells”
Jessica Vitos (IRB Barcelona, SPAIN)
“p38α: a double-edged swiss knife in non-small cell lung cancer”
Antonio Maraver (IRCM, France)
“Identification of new regulators of the Notch pathway in KRASG12V-driven NSCLC”

18:00h – 18:15h    CLOSING REMARKS
20:00h                   GALA DINNER


Marisol Ripa, Center for Applied Medical Research (CIMA, SPAIN) | msripa@unav.es

Andrew Solomon, Center for Applied Medical Research (CIMA, SPAIN) | asolomon@unav.es

Tlf: +34 948 194 700

More information



    Julia Elizalde Urmeneta
    Directora de Comunicación Corporativa
    Tfno: +34 948 29 31 30
  • contacto_ok